Disappointment Guidance Aftermath... 2 Trillion Won Vanished from Healthcare Data Giant in One Day

IQVIA HOLDINGS INC., a U.S.-based healthcare data and clinical trial outsourcing company, closed down 5.33% at $182.45 on the New York Stock Exchange on the 10th. Its market capitalization lost approximately $1.57 billion—around 2 trillion KRW—as more than 1.78 million shares changed hands, exceeding recent trading averages amid heightened selling pressure.

On February 5, IQVIA reported fourth-quarter 2025 revenue of $4.36 billion and earnings per share of $3.42, reflecting double-digit sales growth year-over-year. However, its full-year 2026 adjusted EPS guidance of $12.55–$12.85 fell short of Wall Street expectations, triggering an immediate roughly 8% share price decline and a continued downtrend. (Source: ir.iqvia.com)

Born from the merger of IMS Health and Quintiles, IQVIA ranks among the world’s leading CROs and healthcare data firms. It provides clinical trial outsourcing and real-world data analytics services to pharmaceutical, biotech, and medical device companies. By leveraging vast medical databases and AI-driven analytics, IQVIA offers an essential infrastructure that supports the entire drug development and commercialization lifecycle, keeping its long-term growth outlook strong.